Assessment of Routine Measles Vaccine Effectiveness Among Children Referring to Tertiary Fever Hospital in Egypt

John Rene Labib¹, *, Eman Hany Elsebaie², Shaimaa A.M. Abd El Fatah ², Silvia Farouk Shalaby² and Engy El Khateeb³

¹Pediatrics Department, Faculty of Medicine, Cairo University, Cairo, Egypt
²Public Health Department, Faculty of Medicine, Cairo University, Cairo, Egypt
³Clinical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

*Corresponding author: Pediatrics Department, Faculty of Medicine, Cairo University, Cairo, Egypt. Email: johnrenelabib@gmail.com

Received 2019 February 23; Revised 2019 May 30; Accepted 2019 June 13.

Abstract

Background: Measles is one of the leading causes of childhood morbidity and mortality in the world despite the availability of a relatively inexpensive, safe, and effective vaccine.

Objectives: The study aimed to evaluate measles vaccine effectiveness as one of the fundamental actions to eliminate measles infection. The specific objectives were to estimate the measles vaccine effectiveness at the level of under 12-year-old children population using the Egyptian surveillance data for cases seeking medical care at Embaba Fever Hospital between March 2017 and February 2018 and to determine the trend of measles virus infection during the same period.

Methods: This hospital-based cross-sectional analytical study was conducted at Embaba Fever Hospital in Giza Governorate for the evaluation of measles vaccine effectiveness. In total, 466 patients were enrolled in the study and investigated clinically and laboratory to confirm the diagnosis of measles.

Results: Of the 466 children, 69 (14.8%) tested positive for measles IgM antibodies. Children in the 1 - 4 year age group had the highest positivity rate to measles antibodies (43.5%), followed by the age group of ≥ 5 years (29%) and the age group of < 1 year (27.5%). The overall estimated vaccine effectiveness was 80.7% (95% CI: 63.7 - 90.8%) for the one-dose measles-mumps-rubella (MMR) and 91.8% (95% CI: 88.0 - 94.5%) for the two-dose vaccine.

Conclusions: Measles infection is still high among vaccinated and unvaccinated children in Egypt. Therefore, it is suggested that a sustainable plan be developed for achieving high vaccination coverage among children younger than five years of age.

Keywords: Measles Infection, Vaccine Effectiveness, Fever

1. Background

Measles is still a highly infectious disease in children leading to morbidity and mortality worldwide regardless of the availability of a relatively inexpensive, efficient, safe vaccine (1, 2). The incidence differs along the years from 10% to 15%, with a noticeable increase to more than 50% during outbreaks (3, 4). The factors predisposing people to the disease may include poverty, overcrowdedness, malnutrition, vitamin A deficiency, poor hygiene, improper immunization, and decreased immunity (5). The poor immunization coverage rate is reported by studies conducted in different community settings leaving some at-risk children to start outbreaks (6, 7). Moreover, inadequate surveillance and low response capacity in any country can endanger its population (8).

In Egypt, in 1977, measles compulsory vaccination started with a coverage rate ranging from 50% to 90%. However, outbreaks of measles continued to happen during the years 1980 - 1999 at two to four-year intervals. In 1999, the implementation of the compulsory, routine second dose of the measles-mumps-rubella (MMR) vaccine initiated. Along with the start of the immunization campaign from 2000 to 2003 directed to children within the age range of 6 to 16 years, the reported measles cases dramatically decreased (9).

Egypt in 2002 declared the establishment of goals for the elimination of measles by the year 2010 using the UNICEF/WHO strategy for sustainable reduction of measles mortality (10). In 2005 - 2007, large-scale rubella and measles outbreaks occurred that directed the Egyptian health authorities to change the action plan goals of 2010. During 2008 - 2009, a national measles-rubella immunization campaign was implemented at two phases targeting...
children and adolescents aged 2 to 20 years. This campaign recorded a coverage rate of more than 95% (9).

To achieve the 2010 goals, another national vaccination campaign for measles and rubella was conducted in the period from October to November 2015 by the Ministry of Health and Population (MOHP) in collaboration with WHO and UNICEF. The campaign focused on the vaccination of 24 million children between the age of 9 months and 10 years. It was implemented all over Egyptian governorates in schools, nurseries, and health care facilities (11). Despite this success, there were an estimated 222 measles cases in Egypt in 2016 (12).

Measles elimination requires not only a high coverage (> 95%) with an effective vaccine, but also a strong competent health system capable of reaching every child in the community settings (13). Moreover, accurate and complete data on vaccination coverage rates should be available to assess and monitor the performance of vaccination services at different community levels to support public health planning, allocate resources, measure the impact of interventions, and raise attention to the areas of program weaknesses.

2. Objectives

Based on the previously mentioned facts, the aim of the present study was to evaluate measles vaccine effectiveness as one of the fundamental actions to eliminate measles virus infection. The specific objectives were to estimate measles vaccine effectiveness at the level of under 12-year-old children population using the Egyptian surveillance data for cases seeking medical care at Embaba Fever Hospital between March 2017 and February 2018 and to determine the trend of measles virus infection for the given children population during the same study period.

3. Methods

3.1. Study Design, Period, and Setting

This was a hospital-based cross-sectional analytical study conducted at Embaba Fever Hospital at Giza Governorate for the evaluation of measles vaccine effectiveness. The hospital admits about 14000 patients annually. The study was done over a period of one year starting from March 2017.

3.2. Working Definitions

The World Health Organization (WHO) case definition of measles was used for clinical diagnosis of measles’ cases including, “An acute illness characterized by Generalized, maculopapular rash lasting ≥ 3 days, temperature ≥101°F or 38.3°C, and cough, coryza, or conjunctivitis” (14). Moreover, according to the WHO, a “probable case” of measles is defined as an illness that, “In the absence of a more likely diagnosis, meets the clinical description with no epidemiologic linkage to a laboratory-confirmed measles case; and noncontributory or no measles laboratory testing”. A “confirmed case” of measles is recognized as, “An acute febrile rash illness with isolation of the measles virus from a clinical specimen; or detection of measles-virus specific nucleic acid from a clinical specimen using polymerase chain reaction; or IgG seroconversion or a significant rise in measles immunoglobulin G antibody using any evaluated and validated method; or a positive serologic test for measles immunoglobulin M antibody; or a direct epidemiologic linkage to a case confirmed by one of the above-mentioned methods. Temperature does not need to reach ≥ 101°F/38.3°C and rash does not need to last ≥ 3 days.” (14).

Vaccination status was interpreted according to the number of vaccine doses received, as receiving one dose, two or more doses, or not receiving a dose at all. Any doses recorded within two weeks before the disease onset were excluded from the analysis.

3.3. Study Sample

A purposive sampling technique was used where all children admitted to Embaba Fever Hospital with symptoms suggestive of measles or measles like-illness during the study period were included, making 466 patients in total. They were investigated clinically and laboratory to confirm the diagnosis of measles at the outpatient clinic of Embaba Fever Hospital.

3.4. Study Tools and Data Collection

The study was conducted among children aged less than 12 years. Data were obtained using a questionnaire during structured interviews held by a pediatrician and an epidemiologist. Demographic data, immunization status, and the onset date of symptoms and signs (especially the rash) were obtained for the whole sample.

3.5. Laboratory Workup

To serologically confirm the cases, blood samples were collected and evaluated by a clinical pathology physician. The detection of anti-measles specific IgM antibodies was used for laboratory confirmation. Sterile labeled dry bottles containing anticoagulants were used for specimens’ collection (about 2 mL of blood from each child). In the laboratory, the serum was separated from the blood by centrifugation and stored in sterile Eppendorf tubes until processing. Measles IgM enzyme-linked immunosorbent
3.6. Statistical Analysis

The measles vaccine effectiveness was calculated according to the following equation:

\[
\text{Vaccine effectiveness} = \frac{\text{number of IgM-VE children}}{\text{Total number of children}}
\]

The proportion of IgM-VE children within each category (sex, age, and vaccination status groups) with its 95% confidence interval was calculated.

The collected data were analyzed using the Statistical Package for Social Sciences (SPSS) Software (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.). Data were summarized using mean and standard deviation statistics for quantitative variables and frequency and percentage for qualitative variables. Tests of normality of data (e.g., Kolmogorov-Smirnov test) showed that the data were not normally distributed. Therefore, non-parametric tests such as the Mann-Whitney test were used in univariable comparisons to quantify the associations between continuous variables while the chi-square test was used for qualitative variables. P values of less than 0.05 were considered statistically significant. Multivariate analysis using binary logistic regression model was done to explore the predictive ability of a set of categorical variables (sex, age, and vaccination status) for measles infection; the model determined the factors that predicted the likelihood of children involved with measles and the factor that best predicted the outcome when it had been controlled for the effects of other variables.

3.7. Ethical Considerations

The study protocol was approved by the Research Ethics Committee of the Faculty of Medicine, Cairo University, and by the responsible managers of the Fever Hospital. Informed consent was attained directly from the legal guardian of each child prior to data and sample collection following the explanation of the study objectives and methods. All procedures for data collection were treated with confidentiality according to the Helsinki declaration of biomedical ethics (15).

4. Results

In total, 466 children (including 54.5% males and 45.5% females) took part in this study. The mean age of the children was 4.2 ± 2.8 years ranging from 3 months to 12 years.

There were 69 (14.8%) children with positive results for measles IgM antibodies, with the highest percentage being in the 1 - 4 year age group (43.5%) (Table 1). Regarding the vaccination status, 60.3% of the children had evidence of vaccination with two or more doses while 33% of the children had not been vaccinated (Table 2). In the male group, the frequency of unvaccinated, positive-IgM children (23.1%) was significantly higher than the frequency of those who received ≥ 2 doses and tested positive (10.1%) (P value < 0.05), demonstrating the vaccine effectiveness of 89.9%. In the female group, this was quite the same (30.2% IgM positivity in unvaccinated children versus 6.1% in children receiving ≥ 2 doses) but with higher vaccine effectiveness (93.9%). In the age group of 1 - 4 years, the fully vaccinated (i.e., vaccination with ≥ 2 doses) positive-IgM children (8.8%) were significantly lower in frequency than unvaccinated children or those who received one dose, giving the vaccine effectiveness of 91.2%. This was nearly the same in the age group for ≥ 5 years (7.4%) (Table 3).

Table 4 shows that only vaccination with two doses or more made a unique statistically significant contribution to the direct logistic regression model. The odds of being IgM positive was lower in children who were vaccinated with two or more doses than in children who were not vaccinated when adjusted for all other factors. Figure 1 shows the trend of measles cases along the study period where there was a peak of increase in cases from April to June 2017 and again from December 2017 to February 2018.

5. Discussion

By the use of a measles-specific IgM detection ELISA kit, the study was planned to test measles infection among vaccinated and unvaccinated children presenting fever and
Table 1. Demographic Characteristics of the Tested Positive and Negative Measles IgM Children

| Demographic Characteristics | Measles IgM | Total (N = 466) | P Value |
|----------------------------|------------|----------------|---------|
|                           | +VE (N = 69) | -VE (N = 397)  |         |
| Sex                       |            |                | 0.919   |
| Male                      | 38 (15)    | 216 (85)       |         |
| Female                    | 31 (14.6)  | 181 (85.4)     |         |
| Age, y<sup>a</sup>        |            |                | 0.008<sup>b</sup> |
| Range                     | 0.5 - 10.7 | 0.2 - 12       | 0.2 - 12|
| Mean ± SD                 | 3.4 ± 2.6  | 4.4 ± 2.8      | 4.2 ± 2.8|
| Median                    | 3          | 4.2            | 4       |
| Age groups, y             |            |                |         |
| < 1                       | 19 (26.8)  | 52 (73.2)      | 71 (100)| 0.002<sup>b</sup> |
| 1 - 4                     | 30 (13.4)  | 194 (86.6)     | 224 (100)| 0.409 |
| ≥ 5                       | 20 (11.7)  | 151 (88.3)     | 171 (100)| 0.150 |

<sup>a</sup>Mann-Whitney test  
<sup>b</sup>P value is statistically significant at the level of < 0.05.

Table 2. Vaccination Status of the Tested Positive and Negative Measles IgM Children

| Vaccination Status | Measles IgM | Total (N = 466) | P Value | Vaccine Effectiveness | OR (95% CI) |
|--------------------|------------|----------------|---------|----------------------|-------------|
|                    | +VE (N = 69) | -VE (N = 397)  |         |                      |             |
| Unvaccinated       | 40 (26)    | 114 (74)       | 154 (100)| < 0.001              | Ref.        |
| One dose           | 6 (19.4)   | 25 (80.6)      | 31 (100)| 0.461                | 80.6 (54.4 - 91.5)| 0.684 (0.262 - 1.788) |
| Two doses or more  | 23 (8.2)   | 258 (91.8)     | 281 (100)| < 0.001              | 91.8 (88.2 - 94.6)| 0.254 (0.145 - 0.444) |

Abbreviations: CI, confidence interval; OR, odds ratio; Ref., reference category.

Maculopapular rash at a Tertiary Fever Hospital in Egypt. As recommended by the WHO, the detection of measles IgM remains the best technique for measles diagnosis (16). We must bear in mind that the cases gathered during the study period may have not presented the true clinical situation of maculopapular rash infections happening due to the underreporting of several rash infections in different sectors of the country and only those who came to the Fever Hospital were enrolled in the current study. The prevalence of recent measles infection (14.8%) established in this study emphasizes that the burden of infection in Egypt is yet high despite the integration of measles vaccination as part of the Expanded Program of Immunization (EPI) and implementing the vaccine in routine campaigns for vaccination of one-year-old children.

About one-third of the children who gave positive measles-specific IgM had received two or more doses of measles vaccine (vaccine effectiveness of 91.8%). This goes in accordance with many recent similar studies that displayed high measles vaccine effectiveness (17, 18). Measles infection among formerly vaccinated children could be due to vaccine failure, either primary or secondary. The improper vaccine dosage, inadequate cold-chain system, and host-specific factors such as the persistence of maternally acquired immunity are among the primary causes of vaccine failure (19, 20). The secondary vaccine failure could be attributed to the nutritional status of children or the presence of underlying diseases. The estimation of vaccine effectiveness is an important factor in evaluating an immunization schedule and its changes. It adjudges whether the measles vaccine is protective at the population level or not. In agreement with the findings from other studies, vaccination coverage gaps may partake to measles outbreaks and constitute a serious hindrance for measles elimination (18).

The sex distribution was not significant although a noticeably high percentage of male children (55.1%) were infected in comparison with females (44.9%). This differs from former studies that reported a statistical association among female children with elevated infection rates compared to their male counterparts (21, 22). Concerning age, infection rates showed higher values up to the age of five years. This finding is in accordance with other study findings in Africa where measles infection mainly influenced...
Table 3. Comparison Between Tested Positive and Tested Negative Measles IgM Children Regarding Vaccination Status Based on Sex and Age Groups

| Vaccination Status | Measles IgM | P Value | Vaccine Effectiveness | OR (95% CI) |
|-------------------|-------------|---------|-----------------------|-------------|
|                   | +VE (N = 69) | -VE (N = 397) |               |               |
| **Sex**           |             |         |                       |             |
| Male              |             |         |                       |             |
| Unvaccinated      | 21 (23.1)   | 70 (76.9) | 0.007                 | Ref. Ref.   |
| One dose          | 2 (14.3)    | 12 (85.7) | 0.942                 | 85.7 (61.5 - 96.8) | 0.556 (0.115 - 2.682) |
| Two doses or more | 15 (10.1)   | 134 (89.9) | 0.009               | 89.9 (84.3 - 94) | 0.373 (0.181 - 0.769) |
| Female            |             |         |                       |             |
| Unvaccinated      | 19 (30.2)   | 44 (69.8) | < 0.001               | Ref. Ref.   |
| One dose          | 4 (23.5)    | 13 (76.5) | 0.280                 | 76.5 (53.3 - 91.5) | 0.713 (0.206 - 2.470) |
| Two doses or more | 8 (6.1)     | 124 (93.9) | < 0.001              | 93.9 (88.9 - 97.1) | 0.149 (0.061 - 0.366) |
| **Age groups, y** |             |         |                       |             |
| 1 - 4             |             |         |                       |             |
| Unvaccinated      | 10 (28.6)   | 25 (71.4) | 0.004                 | Ref. Ref.   |
| One dose          | 6 (20)      | 24 (80)   | 0.255                 | 80 (63.3 - 91.2) | 0.625 (0.397 - 1.987) |
| Two doses or more | 14 (8.8)    | 145 (91.2) | 0.002                | 91.2 (86.9 - 94.9) | 0.241 (0.097 - 0.603) |
| ≥ 5               |             |         |                       |             |
| Unvaccinated      | 11 (22.9)   | 37 (77.1) | 0.005                 | Ref. Ref.   |
| One dose          | 0 (0)       | 1 (100)   | 0.716                 | 100 (NA) | NA |
| Two doses or more | 9 (7.4)     | 113 (92.6) | 0.006               | 92.6 (87.9 - 96.3) | 0.268 (0.103 - 0.697) |

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; Ref., reference category.

NB: Patients aged less than one year were excluded, as none of them was vaccinated.

Table 4. Multivariate Logistic Regression Model Demonstrating Factors Affecting Tested Positive and Tested Negative Measles IgM

| Variables       | P Value | OR  | 95% CI          |
|-----------------|---------|-----|-----------------|
| **Sex**         |         |     |                 |
| Male            | 0.877   | 0.957 | 0.563 - 1.628   |
| Female          | Ref.    | Ref. | Ref.            |
| **Age groups, y** |       |     |                 |
| < 1             | Ref.    | Ref. | Ref.            |
| 1 - 4           | 0.868   | 1.071 | 0.478 - 2.398   |
| ≥ 5             | 0.637   | 0.829 | 0.380 - 1.809   |
| **Vaccination status** | | | |
| Unvaccinated    | Ref.    | Ref. | Ref.            |
| One dose        | 0.375   | 0.644 | 0.209 - 1.805   |
| Two doses or more | < 0.001 | 0.252 | 0.130 - 0.490   |

Abbreviations: CI, confidence interval; OR, odds ratio; Ref., reference category.

Arch Pediatr Infect Dis. 2019; 7(3):e90407.
In many low- and middle-income countries, such as Egypt, a second-dose opportunity to children of different ages through measles complementary immunization campaigns (regardless of the previous history of vaccination) is mandatory to achieve a wide vaccination coverage and get to the children who miss their routine measles vaccine dose (32).

5.1. Conclusions

The study results showed that measles infection is still high in Egypt regardless of the vaccination status of children. Therefore, it is suggested that a national plan be developed to achieve higher vaccination coverage among under-five children. Target groups at risk during outbreaks are in need of a supplemental dose of immunization. Finally, it is important to perform regular vaccine effectiveness analyses to exclude possible vaccine failure as a contributing factor.

Acknowledgments

The authors are thankful to the Chairman of Embaba Fever Hospital for performing this study. We also thank the nursing staff who helped in data and specimens collection. The research team is especially thankful to all children and their guardians.

Footnotes

Authors’ Contribution: Each author has made substantial contributions to the following: John Rene Labib: the conception and design of the study, drafting the article or revising it critically for important intellectual content, final approval of the version to be submitted. Eman Hany Elsebaie: acquisition of data, drafting the article and final approval of the version to be submitted. Shaimaa A.M. Abd El Fatah: acquisition of data, analysis, and interpretation of data, drafting the article and final approval of the version to be submitted. Silvia Farouk Shalaby: drafting the article and final approval of the version to be submitted. Engy El Khateeb: acquisition of data, supervision of laboratory results, drafting the article and final approval of the version to be submitted.

Conflict of Interests: The authors declare no conflicts of interest.

Ethical Approval: The study protocol was approved from the Research Ethical Committee at the Faculty of Medicine, Cairo University and also form the responsible managers of the Fever Hospital. All procedures for data collection were treated with confidentiality according to the Helsinki declarations of biomedical ethics.

Funding/Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Patient Consent: Informed consent was attained directly from the legal guardian of each child prior to data and samples collection after explanation of the study objectives and methods.

References

1. World Health Organization. Progress in reducing global measles deaths: 1999-2002. The Weekly Epidemiological Record; 2004.
2. Park K. Park’s textbook of preventive and social medicine. 19th ed. India: Bhanoit Publishers; 2007.
3. Mishra A, Mishra S, Lahariya C, Jain P, Bhadoriya RS, Shrivastav D, et al. Practical observations from an epidemiological investigation of a measles outbreak in the state of India. Indian J Community Med. 2009;34(2):217-21. doi: 10.4103/0970-0212.51234. [PubMed:19966957]. [PubMed Central: PMC2781117].
4. Bhart B, Bharti S. Measles in a hilly hamlet of northern India. Indian J Pediatr. 2002;69(12):1033-5. [PubMed:12557954].
5. Sharma MK, Bhatia V, Swami HM. Outbreak of measles amongst vaccinated children in a slum of Chandigarh. Indian J Med Sci. 2004;58(2):47-53. [PubMed:14995766].
6. Bhatia V, Swami HM, Rai SK, Gulati S, Verma A, Parashar A, et al. Immunization status in children. Indian J Pediatr. 2004;71(4):313-5. doi: 10.1007/bf02274097.
7. Puri A, Gupta VK, Chakravarti A, Mehr M. Measles vaccine efficacy evaluated by case reference technique. Indian Pediatr. 2002;39(6):556-60. [PubMed:12084949].
8. Nelesone T, Durrheim DN, Speare R, Kiedrzynski T, Melrose WD. Short communication: Strengthening sub-national communicable disease surveillance in a remote Pacific Island country by adapting a successful African outbreak surveillance model. Trop Med Int Health. 2006;11(1):21-27. doi: 10.1111/j.1365-3156.2005.01534.x. [PubMed:16398751].
9. El Sayed N, Kandeel N, Barakat I, Moussa I, Alexander J, Naour B, et al. Progress toward measles and rubella elimination in Egypt. J Infect Dis. 2011;204 Suppl 1:S318-24. doi: 10.1093/infdis/jir123. [PubMed:21666180].
10. Ahmed H. Updates in the situation of the Eastern Mediterranean region. 13th annual meeting measles and Rubella initiatives American Red Cross-national headquarters. 2014 September 9-10; Washington DC. Vaccine preventable diseases and immunization WHO/EMRO; 2014.
11. World Health Organization. Measles-Rubella campaign, phase one, 2 May-30 November 2008, Egypt, 2018, cited 2018 November 24. Available from: http://jid.oxfordjournals.org/content/204/suppl_1/S318. full.
12. World Health Organization. Measles-cases, 2017. [cited 2018 December 18]. Available from: https://knoema.com/atlas/Egypt/topics/Health/CommunicableDiseases/Measles-cases/2017.
13. World Health Organization. Global Vaccine Action Plan (GVAP) Secretariat report 2015 measles. 2015, cited 2018 November 29. Available from: http://www.who.int/immunization/sage/meetings/2015/october/8_GVAP_Secretariat_report_2015_Measles.pdf.
14. National Institute of Communicable Diseases. Manual for investigation and control of outbreak of measles. Govt. of India, Delhi’s: Director General of Health Services; 2006, cited 2018 December 14. Available from: http://www.ncdc.gov.in/.
15. Thompson A, Temple N. Ethics, medical research, and medicine: Commercialism versus environmentalism and social justice. Springer Science & Business Media; 2001. doi: 10.1007/978-94-009-0794-8.

Arch Pediatr Infect Dis. 2019;7(3):e90407.
16. World Health Organization. *Surveillance guidelines for measles, Rubella and Congenital Rubella Syndrome in the WHO European region*. 2009, [cited 2018 November 25]. Available from: www.who.int/immunization/documents/measles_rubella_eur_08_5082738/en/.

17. Musa S, Topalovic B, Catic S, Smajlagic Z. Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. *Cent Eur J Public Health*. 2018;26(2):79-82. doi: 10.2101cejph.4754. [PubMed: 30102491].

18. Pillsbury A, Quinn H. An assessment of measles vaccine effectiveness, Australia, 2006-2012. *Western Pac Surveill Response J*. 2015;6(3):43–50. doi: 10.5365/WPSAR.2015.6.2.007. [PubMed: 26668766]. [PubMed Central: PMC4679157].

19. Aylward RB, Clements J, Olive JM. The impact of immunization control activities on measles outbreaks in middle and low income countries. *Int J Epidemiol*. 1997;26(3):662-9. doi: 10.1093/ije/26.3.662. [PubMed: 9222794].

20. Vormalovich MA, Hubschen JM, Semeiko GV, Samoilovich EO, Muller CP. Human parvovirus B19 surveillance in patients with rash and fever from Belarus. *J Med Virol*. 2012;84(6):973–8. doi: 10.1002/jmv.23294. [PubMed: 22499021].

21. Crawley J, Sismanidis C, Goodman T, Milligan P, W. H. O. Advisory Committee on serological responses to vaccines used in the Expanded Programme on Immunization in infants receiving Intermittent Preventive Treatment for malaria. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: Results from five randomised controlled trials. *Lancet*. 2012;380(9846):1001–10. doi: 10.1016/S0140-6736(12)60775-2. [PubMed: 22850358].

22. Magalhaes Ide M, Martins RV, Vianna RO, Moyes N, Afonso LA, Oliveira SA, et al. Detection of human herpesvirus 7 infection in young children presenting with exanthema subitum. *Mem Inst Oswaldo Cruz*. 2011;106(3):373-7. doi: 10.1590/S0074-02762011000300020. [PubMed: 21655839].

23. Dossetor J, Whittle HC, Greenwood BM. Persistent measles infection in malnourished children. *Br Med J*. 1977;1(6077):1633–5. doi: 10.1136/bmj.1.6077.1631. [PubMed: 876999]. [PubMed Central: PMC1607735].

24. Moss WJ. Measles control and the prospect of eradication. *Curr Top Microbiol Immunol*. 2009;330:173–89. [PubMed: 1920310].

25. Ogundiji OT, Okonko IO, Adu FD. Determination of measles hemagglutination inhibiting antibody levels among school children in Ibadan, Nigeria. *J Immunoassay Immunochem*. 2013;34(2):208–17. doi: 10.1080/13218789.2012.699496. [PubMed: 23537014].

26. Pomerai KW, Mudiyiradima RF, Gombe NT. Measles outbreak investigation in Zaka, Masvingo province, Zimbabwe, 2010. *BMC Res Notes*. 2012;5(1):687. doi: 10.1186/1756-0500-5-687. [PubMed: 23253554]. [PubMed Central: PMC354261].

27. Jasem J, Marof K, Nawar A, Monirul Islam KM. Epidemiological analysis of measles and evaluation of measles surveillance system performance in Iraq, 2006-2010. *Int J Infect Dis*. 2012;16(3):e166–71. doi: 10.1016/j.ijid.2011.10.002. [PubMed: 2292584].

28. Doshi RH, Mukadi P, Shidi C, Mulumba A, Hoff NA, Gerber S, et al. Field evaluation of measles vaccine effectiveness among children in the Democratic Republic of Congo. *Vaccine*. 2015;33(29):3407–14. doi: 10.1016/j.vaccine.2015.04.067. [PubMed: 25937498].

29. Siennicka J, Stefanoff P, Rogalska J, Trzcinska A. Etiology of measles suspect cases reported in 2006-2007 in Poland. *Przegl Epidemiol*. 2012;66(1):39-44. [PubMed: 22735834].

30. Onoja AB, Adeniji AJ. Measles complications in a Nigerian hospital setting. *Clin Rev Opin*. 2013;3:528-23. doi: 10.5897/CR02.008.

31. Onoja AB, Adeniji AJ. Kinetics of measles antibody by hemagglutination inhibition assay in children in south-west and north-central Nigeria. *Int J Infect Dis*. 2013;17(7):e552–5. doi: 10.1016/j.ijid.2013.02.001. [PubMed: 2350540].

32. Portnoy A, Jit M, Helleringer S, Verguet S. Impact of measles supplementary immunization activities on reaching children missed by routine programs. *Vaccine*. 2018;36(1):70-8. doi: 10.1016/j.vaccine.2017.10.080. [PubMed: 29174680]. [PubMed Central: PMC5949217].